FDA Expands Guselkumab Approval to Crohn's Disease

(MedPage Today) -- The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday.
An interleukin (IL)-23 inhibitor that also binds...